AcelRx Pharmaceuticals Q1 2024 Earnings Preview
| TLPH Stock | 0.64 0.02 3.23% |
Under 72 percent of all Talphera's traders are curious in acquiring. The analysis of overall sentiment of trading Talphera stock suggests that a large number of investors are confidant at this time. Talphera's investing sentiment shows overall attitude of investors towards Talphera.
Talphera |
AcelRx Pharmaceuticals is scheduled to announce Q1 earnings results on Tuesday, May 14th, after market close. The consensus EPS Estimate is -0.21. Over
Read at seekingalpha.com
 |
Talphera Fundamental Analysis
We analyze Talphera's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Talphera using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Talphera based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Short Ratio
Short Ratio Comparative Analysis
Talphera is currently under evaluation in short ratio category among its peers. Short Ratio is typically used by traders and speculators to identify trends in current market sentiment for a particular equity instrument. In its simple terms this ratio shows how many days it will take all current short sellers to cover their positions if the price of a stock begins to rise.
Talphera Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Talphera stock to make a market-neutral strategy. Peer analysis of Talphera could also be used in its relative valuation, which is a method of valuing Talphera by comparing valuation metrics with similar companies.
Peers
Talphera Related Equities
| TEVA | Teva Pharma | 3.66 | ||||
| EBS | Emergent Biosolutions | 0.50 | ||||
| NBIX | Neurocrine Biosciences | 0.34 | ||||
| HLN | Haleon Plc | 0.10 | ||||
| ALVO | Alvotech | 1.65 |
Complementary Tools for Talphera Stock analysis
When running Talphera's price analysis, check to measure Talphera's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Talphera is operating at the current time. Most of Talphera's value examination focuses on studying past and present price action to predict the probability of Talphera's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Talphera's price. Additionally, you may evaluate how the addition of Talphera to your portfolios can decrease your overall portfolio volatility.
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data |